edaravone (e-dar-a-vone) Radicava

 Indications

Amyotrophic lateral sclerosis (ALS).

Action

Unknown. Therapeutic Effects: Improved functional

ability.

Pharmacokinetics

Absorption: IV administration results in complete

bioavailability.

Distribution: Unknown.

Protein Binding: 92%.

Metabolism and Excretion: Metabolized via sulfation

and glucuronidation into inactive metabolites.

Primarily eliminated in urine (1% as unchanged drug).

Half-life: 4.5–6 hr.

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION

PO unknown 1 hr unknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Sulfite allergy.

Use Cautiously in: OB: Safety not established; Lactation:

Consider benefits of breast feeding against possible

risk to infant; Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: headache. Derm: contusion, dermatitis, eczema,

fungal infection (tinea). GU: glycosuria.

Neuro: gait abnormality. Misc: HYPERSENSITIVITY REACTIONS

(including anaphylaxis).

Interactions

Drug-Drug: None known.

Route/Dosage

IV (Adults): 60 mg once daily for 14 day, followed by

a drug-free period of 14 days. Each subsequent cycle

should consist of 60 mg once daily for 10 days out of 14

days, followed by a drug-free period of 14 days.

Availability

Premixed infusion: 30 mg/100 mL.